

Paper #3

SHEET 1 OF 5

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)	ATTY. DOCKET NO. ELITRA.001DV1	APPLICATION NO. Unknown	J1036 U.S. PTO 09/912020 07/23/01
	APPLICANT Zyskind, et al.		
	FILING DATE Herewith	GROUP Unknown	

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
	1	4,622,297	11/11/86	Kappner, et al.			
	2	4,980,281	12/25/90	Housey, et al.			
	3	5,190,931	03/02/93	Inouye			
	4	5,208,149	05/04/93	Inouye, et al.			
	5	5,266,464	11/30/93	Housey, et al.			
	6	5,272,065	12/21/93	Inouye, et al.			
	7	5,569,588	12/09/96	Ashby, et al.			
	8	5,585,277	12/17/96	Bowie, et al.			
	9	5,688,655	11/08/97	Housey, et al.			
	10	5,756,305	05/26/98	Timberlake, et al.			
	11	5,821,076	10/13/98	Timberlake, et al.			
	12	5,877,007	03/02/99	Housey, et al.			
	13	5,965,352	10/12/99	Stoughton, et al.			
	14	6,015,669	01/18/00	Holden			
	15	6,174,678	01/16/01	Menzel, et al.			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	16	WO 95/06132	03/02/95	PCT				
	17	WO 96/23075	08/01/96	PCT				
	18	WO 96/40979	12/19/96	PCT				
	19	WO 97/11690	04/03/97	PCT				
	20	WO 97/23642	07/03/97	PCT				
	21	WO 97/42210	11/13/97	PCT				
	22	WO 98/03533	01/29/98	PCT				
	23	WO 99/23244	05/14/99	PCT				
	24	WO 99/36554	07/22/99	PCT				

EXAMINER

DATE CONSIDERED


1.7.03

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)	ATTY. DOCKET NO. ELITRA.001DV1	APPLICATION NO. Unknown
	APPLICANT Zyskind, et al.	
	FILING DATE Herewith	GROUP Unknown


FOREIGN PATENT DOCUMENTS								
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
A	25	WO 99/43338	09/02/99	PCT				
	26	WO 99/49888	10/07/99	PCT				

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
A	27	Austin, A. E., et al., <i>Journal of Bacteriology</i> , 172:5312-5325, 1990, "Genetic Analysis of Lipopolysaccharide Core Biosynthesis by <i>Escherichia coli</i> k12 Insertion Mutagenesis of the RFA Locus."
	29	Lee, N. G., et al., <i>Infection and Immunity</i> , 63(3):818-824, 1995, "Molecular Cloning and Characterization of the Nontypable Haemophilus Influenzae-2019 rfaE Gene Required for Lipopolysaccharide Biosynthesis."
	30	Valvano, M. A., et al., <i>Journal of Bacteriology</i> , 182:488-497, 2000, "The rfaE Gene from <i>Escherichia coli</i> Encodes a Bifunctional Protein Involved in Biosynthesis of the Lipopolysaccharide Core Precursor ADP-L-glycero-D-manno-heptose."
	31	Van Heeswijk, W. C., et al., <i>Molecular Microbiology</i> , 9:443-457, 1993, "The Genes of the Glutamine Synthetase Adenylation Cascade are not Regulated by Nitrogen in <i>Escherichia coli</i> ."


EXAMINER 	DATE CONSIDERED 1-7-03
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)	ATTY. DOCKET NO. ELITRA.001DV1	APPLICATION NO. Unknown
	APPLICANT Zyskind, et al.	
	FILING DATE Herewith	GROUP Unknown

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
	32	4,906,742	3/6/90	Young et al.			
	33	5,679,523	10/21/97	Li et al.			
	34	5,846,772	12/8/98	Hodgson et al.			
	35	5,854,020	12/29/98	Hodgson et al.			
	36	5,858,709	1/12/99	Hodgson et al.			
	37	5,869,290	2/9/99	Freeman et al.			
	38	5,882,643	3/16/99	Lonetto			
	39	5,885,572	3/23/99	Gentry et al.			
	40	5,891,667	4/6/99	Hodgson et al.			
	41	5,910,414	6/8/99	Gwynn et al.			
	42	5,955,275	9/21/99	Kamb			
	43	6,020,121	2/1/00	Bao et al.			
	44	6,037,123	3/14/00	Benton et al.			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	45	0816511 A1	1/7/98	EP				
	46	0837142 A1	4/22/98	EP				
	47	0891984 A2	1/20/99	EP				
	48	0889123 A2	1/7/99	EP				
	49	0889129 A2	1/7/99	EP				
	50	0892056 A2	1/20/99	EP				
	51	0892064 A2	1/20/99	EP				
	52	0894806 A1	2/3/99	EP				
	53	0897008 A2	2/17/99	EP				

EXAMINER

DATE CONSIDERED

1-7-03

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)	ATTY. DOCKET NO. ELITRA.001DV1	APPLICATION NO. Unknown
	APPLICANT Zyskind, et al.	
	FILING DATE Herewith	GROUP Unknown

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	54	0906959 A2	4/7/99	EP				
	55	0905247 A2	3/31/99	EP				
	56	0900845 A2	3/10/99	EP				
	57	WO 97/16177	5/9/97	PCT				
	58	WO 97/27212	7/31/97	PCT				
	59	WO 97/48822	12/24/97	PCT				
	60	WO 98/44135	10/8/98	PCT				
	61	WO 97/40851	11/6/97	PCT				
	62	WO 97/37026	10/9/97	PCT				
	63	WO 98/20161	5/14/98	PCT				
	64	WO 98/19162	5/7/98	PCT				
	65	WO 99/28508	6/10/99	PCT				
	66	WO 99/35494	7/15/99	PCT				
	67	WO 99/50462	10/7/99	PCT				
	68	WO 99/52926	10/21/99	PCT				
	69	WO 99/53079	10/21/99	PCT				
	70	WO 99/06839	2/11/99	PCT				
	71	WO 99/61452	12/2/99	PCT				
	72	WO 99/29837	6/17/99	PCT				
	73	WO 99/27128	6/3/99	PCT				
	74	WO 99/27074	6/3/99	PCT				
	75	WO 99/26651	6/3/99	PCT				
	76	WO 99/55729	11/4/99	PCT				
	77	WO 97/272213	7/31/97	PCT				
	78	WO 00/34481	6/15/00	PCT				
	79	WO 98/42854	10/1/98	PCT				
	80	WO 99/02673	1/21/99	PCT				
	81	WO 98/21366	5/22/98	PCT				

EXAMINER


DATE CONSIDERED

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)	ATTY. DOCKET NO. ELITRA.001DV1	APPLICATION NO. Unknown
	APPLICANT Zyskind, et al.	
	FILING DATE Herewith	GROUP Unknown

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
82	Armstrong, K.A. and Fan, D.P., "Essential Genes in the <i>metB-malB</i> Region of <i>Escherichia coli</i> K12," J. BACTERIOL. 126: 48-55 (1975).
83	Biswas, E.E. and Biswas, S.B., "Mechanism and DnaB Helicase of <i>Escherichia coli</i> : Structural Domains Involved in ATP Hydrolysis, DNA Binding, and Oligomerization," BIOCHEM. 38:10919-10928 (1999).
84	Blattner, et al., "The Complete Genome Sequence of <i>Escherichia coli</i> K-12," SCIENCE 277:1453-1474 (1997).
85	den Hollander, J.G., et al., "Synergism Between Tobramycin and Ceftazidime Against a Resistant <i>Pseudomonas Aeruginosa</i> Strain, Tested in an In Vitro Pharmacokinetic Model," ANTIMICROBIA AGENTS & CHEMOTHERAPY 41:95-110 (1997).
86	Fukuoka, T., et al., "Combination Effect Between Panipenem and Vancomycin on Highly Methicillin-Resistant <i>Staphylococcus Aureus</i> ," JAPAN. J. ANTIBIO. 50:411-419 (1997).
87	Gabryelewicz, A., et al., "Multicenter Evaluation of Dual-Therapy (Omeprazol and Amoxycillin) for <i>Helicobacter Pylori</i> -Associated Duodenal and Gastric Ulcer (Two Years of the Observation)," J. PHYSIOL. PHARMACOL. 48 Suppl. 4:93-105 (1997).
88	Gudkov, A.V., and Roninson, I.B., "Isolation of Genetic Suppressor Elements (GSEs) from Random Fragment cDNA Libraries in Retroviral Vectors," METHODS IN MOLEC. BIOL., Vol. 69 cDNA Library Protocols, Edited by I.G. Cowell and C.A. Austin, Humana Press, Inc., Totowa, N.Y.
89	Gutmann, L., et al., "Involvement of Pencillin-Binding Protein 2 with other Pencillin-Binding Proteins in Lysis of <i>Escherichia coli</i> by some Beta-Lactam Antibiotics Alone and in Synergistic Lytic Effect of Amdinocillin (Mecillinam)," ANTIMICROBIAL AGENTS & CHEMOTHERAPY 30:906-912 (1986).
90	Hiasa, H. and Mariani, K.J., "Initiation of Bidirectional Replication at the Chromosomal Origin is Directed by the Interaction Between Helicase and primase," J. BIOL. CHEM. 274:27244-27248 (1999).
91	Holzmayer, T.A., et al., "Isolation of Dominant Negative Mutants and Inhibitory Antisense RNA Sequences by Expression Selection of Random DNA Fragments," NUCLEIC ACIDS RES. 20(4): 711-717 (Feb. 25, 1992).
92	San Martin, C., et al., "Three-Dimensional Reconstructions from Cryoelectron Microscopy Images Reveal an Intimate Complex Between Helicase DnaB and its Loading Partner DnaC," STRUCTURE 6:501-9 (1998).
93	Smith, C.E., et al., "Assessment of the Synergistic Interactions of Levofloxacin and Ampicillin Against <i>Enterococcus Faecium</i> by the Checkerboard Agar Dilution and Time-Kill Methods," DIAGNOS. MICROBIOL. INFECT. DISEASE 27:85-92 (1997).
94	Sutton, M.D., et al., " <i>Escherichia coli</i> DnaA Protein. The N-Terminal Domain and Loading of DnaB Helicase at the <i>E. coli</i> Chromosomal," J. BIOL. CHEM. 273:34255-62 (1998).
95	Wechsler, J.A. and Gross, J.D., " <i>Escherichia coli</i> Mutants Temperature-Sensitive for DNA Synthesis," MOL. GEN. GENETICS 113:273-284 (1971)
96	Yinduo Ji, et al., "Regulated Antisense RNA Eliminates Alpha-Toxin Virulence in <i>Staphylococcus Aureus</i> Infection," J. BACTERIOLOGY 181(21): 6585-6590 (November 1999).
97	Post et al., Nucleotide Sequence of the Ribosomal Protein Gene Cluster Adjacent to the Gene for RNA Polymerase Subunit Beta in <i>Escherichia coli</i> , Proceedings of the National Academy of Sciences of the USA, NY, NY vol.76, no. 4, (1979) pgs. 1697-1701.

S:\DOCS\DOH\DOH-5835.DOC
072301

EXAMINER 	DATE CONSIDERED 1.7.03
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)	ATTY. DOCKET NO. ELITRA.001DV1	APPLICATION NO. 09/912,020
	APPLICANT Zyskind, et al.	
	FILING DATE July 23, 2001	GROUP 1631



TECH CENTER 1600/2900

JAN 6 2002

RECEIVED

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
	1	5,082,767	1/21/92	Hatfield, et al.			
	2	5,142,047	8/25/92	Summerton, et al.			
	3	5,405,775	4/11/95	Inouye, et al.			
	4	5,463,564	10/31/95	Agrafiotis, et al.			
	5	5,574,656	11/12/96	Agrafiotis, et al.			
	6	5,612,180	03/18/97	Brown, et al.			
	7	5,639,603	06/17/97	Dower, et al.			
	8	5,684,711	11/4/97	Agrafiotis, et al.			
	9	5,807,522	9/15/98	Brown, et al.			
	10	5,972,708	10/26/99	Sherratt, et al.			
	11	6,139,817	10/31/00	Palmer, et al.			
	12	6,248,525 B1	06/19/01	Nilsen			
	13	6,303,115 B1	10/16/01	Natsoulis			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	14	WO 95/02823	01/26/95	PCT				
	15	WO 96/17951	06/13/96	PCT				
	16	WO 99/33871	07/8/99	PCT				
	17	WO 99/54728	10/28/99	PCT				
	18	WO 01/09164 A2	02/08/01	PCT				
	19	WO 01/11081 A2	02/15/01	PCT				
	20	WO 01/34809 A2	05/17/01	PCT				
	21	WO 01/49775 A2	07/12/01	PCT				

EXAMINER

DATE CONSIDERED

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. ELITRA.001DV1	APPLICATION NO. 09/912,020
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT Zyskind, et al.	
(USE SEVERAL SHEETS IF NECESSARY)		FILING DATE July 23, 2001	GROUP 1631

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
	22	Almarsson, et al. 1993. Peptide nucleic acid (PNA) conformation and polymorphism in PNA-DNA and PNA-RNA hybrids. <i>Proc. Natl. Acad. Sci. U.S.A.</i> , 90:9542-9546.
	23	Altschul, et al. 1990. Basic local alignment search tool. <i>J. Mol. Biol.</i> , 215:403-10.
	24	Altschul, et al. 1997. Gapped BLAST and PSI-BLAST: A new generation of protein database search programs. <i>Nucleic Acid Res.</i> , 25(17): 3389-3402.
	25	Arigoni, et al. 1998. A genome-based approach for the identification of essential bacterial genes. <i>Nature Biotechnology</i> , 16: 851-856.
	26	Ausubel, et al. (Eds.). 1997. Current Protocols in Molecular Biology, Vol. 1, Unit 1.8.1-1.8.10. John Wiley & Sons, Inc.
	27	Basu, et al. 1997. Synthesis and characterization of a peptide nucleic acid conjugated to a D-peptide analog of insulin-like growth factor 1 for increased cellular uptake. <i>Bioconjugate Chem.</i> , 8:481-488.
	28	Bentin, et al. 1996. Enhanced peptide nucleic acid binding to supercoiled DNA: Possible implications for DNA "breathing" dynamics. <i>Biochemistry</i> , 35:8863-8869.
	29	Cao, et al. 1993. Expression and functional analysis of steroid receptor fragments secreted from <i>Staphylococcus aureus</i> . <i>J. Steroid Biochem Molec. Biol.</i> , 44(1):1-11.
	30	Cotrim, et al. 1999. Isolation of genes mediating resistance to inhibitors of nucleoside and ergosterol metabolism in <i>Leishmania</i> by overexpression/selection. <i>Journal of Biological Chemistry</i> , 274(53):37723-37730.
	31	Demidov, et al. 1995. Kinetics and mechanism of polyamide ("peptide") nucleic acid binding to duplex DNA. <i>Proc. Natl. Acad. Sci. U.S.A.</i> , 92:2637-2641.
	32	Demidov, et al. 1993. Sequence selective double strand DNA cleavage by Peptide Nucleic Acid (PNA) targeting using nuclease S1. <i>Nucl. Acids. Res.</i> , 21(9):2103-2107.
	33	Demidov, et al. 1994. Stability of peptide nucleic acids in human serum and cellular extracts. <i>Biochem. Pharm.</i> , 48(6):1010-1313.
	34	Egholm, et al. 1995. Efficient pH-independent sequence-specific DNA binding by pseudoisocytosine-containing bis-PNA. <i>Nucleic Acids Res.</i> , 23(2):217-222.
	35	Egholm, et al. 1993. PNA hybridizes to complementary oligonucleotides obeying the Watson-Crick hydrogen-bonding rules. <i>Nature</i> , 365:566-568.
	36	Egholm, et al. 1992. Recognition of Guanine and Adenine in DNA by Cytosine and Thymine Containing Peptide Nucleic Acids (PNA). <i>J. Am. Chem. Soc.</i> , 114(24):9677-9678.
	37	Engvall, E. 1980. Enzyme Immunoassay ELISA and EMIT. <i>Meth. Enzymol.</i> , 70:419-439.
	38	Etzold, et al. 1993. Sequence Retrieval System (SRS). SRS-An indexing and retrieval tool for flat file data libraries. <i>Comput. Appl. Biosci.</i> 9(1):49-57.
	39	Gallop, et al. 1994. Applications of Combinatorial Technologies to Drug Discovery. 1. Background and Peptide Combinatorial Libraries. <i>Journal of Medicinal Chemistry</i> , 37(9):1233-1251.
	40	Griffin, et al. 1989. Recognition of Thymine Adenine Base Pairs by Guanine in a Pyrimidine Triple Helix Motif. <i>Science</i> , 245:967-971.
	41	Griffith, et al. Single and bis peptide nucleic acids as triplexing agents: Binding and Stoichiometry. 1995. <i>J. Am. Chem. Soc.</i> , 117:831-832.
	42	Hamilton, et al. 1989. New method for generating deletions and gene replacements in <i>Escherichia coli</i> . <i>J. Bacteriol.</i> , 171(9):4617-4622.
	43	Harvey, et al. 1992. Antisense and antigene properties of peptide nucleic acids. <i>Science</i> , 258:1481-1484.
	44	Hensel, et al. 1995. Simultaneous identification of bacterial virulence genes by negative selection. <i>Science</i> , 269:400-403.
	45	Hirschman, et al. 1996. Peptide nucleic acids stimulate gamma interferon and inhibit the replication of the human immunodeficiency virus. <i>J. Invest. Med.</i> , 44(6):347-351.
	46	Ho, et al. 1989. Site-directed mutagenesis by overlap extension using the polymerase chain reaction. <i>Gene</i> , 77:51-59.
	47	Horton, et al. 1989. Engineering hybrid genes without the use of restriction enzymes: Gene splicing by overlap extension. <i>Gene</i> , 77:61-68.
	48	Huerta, et al. 1998. RegulonDB: A database on transcriptional regulation in <i>Escherichia coli</i> . <i>Nucl. Acids Res.</i> , 26(1):55-59.
	49	Kohler, et al. 1975. Continuous cultures of fused cells secreting antibody of predefined specificity. <i>Nature</i> , 256:495-497.
	50	Krause, et al. 1997. Complexes at the replication origin of <i>Bacillus subtilis</i> with homologous and heterologous dnaA protein. <i>J. Mol. Biol.</i> , 274:365-380.

EXAMINER	DATE CONSIDERED 1.7.03
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. ELITRA.001DV1	APPLICATION NO. 09/912,020
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT Zyskind, et al.	
(USE SEVERAL SHEETS IF NECESSARY)		FILING DATE July 23, 2001	GROUP 1631

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
51	Le Good, et al. 1998. Protein kinase C isotypes controlled by phosphoinositide 3-kinase through the protein kinase PDK1. <i>Science</i> , 281:2042-2045.	
52	Link, et al. 1997. Methods for Generating Precise Deletions and Insertions in the Genome of Wild-Type <i>Escherichia coli</i> : Application to Open Reading Frame Characterization. <i>J. Bacteriol.</i> , 179(20):6228-6237.	
53	Margolis, et al. 2000. Peptide Deformylase in <i>Staphylococcus aureus</i> : Resistance to Inhibition is Mediated by Mutations in the Formyltransferase Gene. <i>Antimicrobial Agents and Chemotherapy</i> , 44(7):1825-1831.	
54	Matsukura, et al. 1988. Synthesis of phosphorothioate analogues of oligodeoxyribonucleotides and their antiviral activity against human immunodeficiency virus (HIV). <i>Gene</i> , 72:343.	
55	Mollegaard, et al. 1994. Peptide nucleic acid DNA strand displacement loops as artificial transcription promoters. <i>Proc. Natl. Acad. Sci. U.S.A.</i> , 91:3892-3895.	
56	Nielsen, et al. 1991. Sequence-selective recognition of DNA by strand displacement with a thymine-substituted polyamide. <i>Science</i> , 254:1497-1500.	
57	Nielsen, et al. 1993. Sequence specific inhibition of DNA restriction enzyme cleavage by PNA. <i>Nucl. Acids. Res.</i> , 21(2):197-200.	
58	Nielsen, et al. 1994. Sequence-specific transcription arrest by peptide nucleic acid bound to the DNA template strand. <i>Gene</i> , 149:139-145.	
59	Norton, et al. 1996. Inhibition of human telomerase activity by peptide nucleic acids. <i>Nature Biotechnol.</i> , 14:615-619.	
60	Pardridge, et al. 1995. Vector-mediated delivery of a polyamide ("peptide") nucleic acid analogue through the blood-brain barrier <i>in vivo</i> . <i>Proc. Natl. Acad. Sci. U.S.A.</i> , 92:5592-5596.	
61	Pearson, W. R. 1990. Rapid and sensitive sequence comparison with FASTP and FASTA. <i>Methods in Enzymology</i> , 183:63- 98.	
62	Pla, et al. 1990. Cloning and expression of the <i>ponB</i> gene, encoding penicillin-binding protein 1B of <i>Escherichia coli</i> , in heterologous systems. <i>J. Bacteriol.</i> , 172(8):4448-4455.	
63	Rossi, et al. 1991. The potential use of catalytic RNAs in therapy of HIV infection and other diseases. <i>Pharmac. Ther.</i> , 50:245-254.	
64	Rudd, K. E. 1998. Linkage map of <i>Escherichia coli</i> K-12, edition 10: The physical map. <i>Micro. & Mol. Biol. Rev.</i> , 62(3):985-1019.	
65	Schena, et al. 1995. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. <i>Science</i> , 270:467-470.	
66	Shalon, et al. 1996. A DNA microarray system for analyzing complex DNA samples using two-color fluorescent probe hybridization. <i>Genome Research</i> , 6:639-645.	
67	Tao, et al. 2000. Drug target validation: Lethal infection blocked by inducible peptide. <i>PNAS</i> , 97(2):783-786.	
68	Uhlmann, et al. 1990. Antisense Oligonucleotides: A New Therapeutic Principle. <i>Chemical Reviews</i> , 90(4):543-584.	
69	Vaitukaitis, et al. 1971. A method for producing specific antisera with small doses of immunogen. <i>J. Clin. Endocr. Metab.</i> , 33:988-991.	
70	Zhang, et al. 1996. Polar Allele Duplication for Transcriptional analysis of consecutive essential genes: Application to a cluster of <i>Escherichia coli</i> fatty acid biosynthetic genes. <i>J. Bacteriol.</i> , 178(12):3614-3620.	
71	Zhang, et al. 2000. Regulated Gene Expression in <i>Staphylococcus aureus</i> for Identifying Conditional Lethal Phenotypes and Antibiotic Mode of Action. <i>Gene</i> , 255:297-305.	

S:\DOCS\DOH\DOH-6287.DOC:dmb
120601

EXAMINER	DATE CONSIDERED 1.7.03
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
ELITRA.001DV1APPLICATION NO.
09/912,020

SHEET 1 OF 2

SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT
BY APPLICANTAPPLICANT
Zyskind, et al.FILING DATE
July 23, 2001GROUP
1631

(USE SEVERAL SHEETS IF NECESSARY)

RECEIVED
MAR 07 2002
TECH CENTER 1600/2300

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
9	1	6,348,582 B1	02/19/02	Black, et al.			
2	2	6,348,582	02/19/02	Black, et al. (Printout of Sequence Listing)			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
9	3	EP 0 786 519 A2	07/30/97	EPO				
	4	EP 0 786 519 A3	07/30/97	EPO				
	5	WO 00/61793	10/19/00	PCT				
	6	WO 01/49721 A2	07/12/01	PCT				

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
9	7	Akerley, et al., "A genome-scale analysis for identification of genes required for growth or survival of <i>Haemophilus influenzae</i> ," <i>PNAS</i> , 99(2):966-971 (2002).
	8	Blattner, et al., "Escherichia coli K12 MG1655 section 101 of 400 of the complete genome," Database accession no. AE000211, XP002181472.
	9	Blattner, et al., "Escherichia coli K12 MG1655 section 298 of 400 of the complete genome," Database accession no. AE000408, XP002181129.
	10	Blattner, et al., "Escherichia coli K12 MG1655 section 305 of 400 of the complete genome," Database accession no. AE000415, XP002181474.
	11	Blattner, et al., "Escherichia coli K12 MG1655 section 337 of 400 of the complete genome," Database accession no. AE000447, XP002181127.
	12	Blattner, et al., "Hypothetical 79.5 kDa protein in MRCA-PCKA intergenic region (0711)," Database accession no. P45800, XP002181475.
	13	Blattner, et al., "Hypothetical protein YCFS precursor," Database accession no. P75954, XP002181473.
	14	Burland, et al., "60 kDa inner-membrane protein," Database accession no. P25714, XP002181128.
	15	Burland, et al., "E. coli; the region from 81.5 to 84.5 minutes," Database accession no. L10328, XP002181130.
	16	Burland, et al., "DNA sequence and analysis of 136 kilobases of the <i>Escherichia coli</i> genome: Organizational symmetry around the origin of replication," <i>Genomics</i> , 16:551-561 (1993).
	17	Ceretti, et al., "Escherichia coli spc ribosomal protein operon," Database accession no. X01563, XP002181131.
	18	De Backer, et al., "An antisense-based functional genomics approach for identification of genes critical for growth of <i>Candida albicans</i> ," <i>Nature Biotechnology</i> , 19:235-241 (2001).

EXAMINER	DATE CONSIDERED
	1.7.03
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

[illegible]

EXAMINER	DATE CONSIDERED 1.7.03
<p>*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.</p>	

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.
ELITRA.001DV1

APPLICATION NO.
09/912,020

RECEIVED

APPLICANT
Zyskind, et al.

MAY 15 2002

FILING DATE
July 23, 2001

GROUP
1634



TECH CENTER 1600/2900

**SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

(USE SEVERAL SHEETS IF NECESSARY)

DIPE
MAY 13 2002
PATENT & TRADEMARK OFFICE

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
	1	5,353,236	10/04/94	Subbiah			
	2	5,744,460	04/28/98	Müller, et al.			
	3	5,869,604	02/09/99	Rousseau, et al.			
	4	6,077,682	06/20/00	Inouye, et al.			
	5	6,156,526	12/05/00	Boriack-Sjodin, et al.			
	6	6,277,564	08/21/01	Berlin, et al.			

FOREIGN PATENT DOCUMENTS									
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION		
							YES	NO	
	7	WO 98/50555	11/12/98	PCT					
	8	WO 99/13893	03/25/99	PCT					

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
	9	Ala'Aldeen, et al. 2001. Unveiling of genetic basis of resistance of <i>S aureus</i> to antibiotics. <i>The Lancet</i> , 357(9264):1218-1219
	10	Appelt, K. 1993. Crystal structures of HIV-1 protease-inhibitor complexes. <i>Perspectives in Drug Discovery and Design</i> , 1:23-48
	11	Bagby, et al. 1994. Unusual helix-containing Greek keys in development-specific Ca ²⁺ -binding protein S. ¹ H, ¹⁵ N, and ¹³ C assignments and secondary structure determined with the use of multidimensional double and triple resonance heteronuclear NMR spectroscopy. <i>Biochemistry</i> , 33:2409-2421.
	12	Bagby, et al. 1995. Solution structure of the C-terminal core domain of human TFIIIB: Similarity to Cyclin A and interaction with TATA-binding protein. <i>Cell</i> , 82:857-867.
	13	Balbes, et al. 1994. "A perspective of modern methods in computer-aided drug design." In Lipkowitz, et al., Eds. <i>Reviews in Computational Chemistry V</i> . Chap. 7, pp. 337-379. New York: VCH Publishers.
	14	Brenner, et al. 2000. <i>Salmonella</i> nomenclature. <i>Journal of Clinical Microbiology</i> , 38(7):2465-2467.
	15	Brunschwig, et al. 1992. A two-component T7 system for the overexpression of genes in <i>Pseudomonas aeruginosa</i> . <i>Gene</i> , 111:35-41.
	16	Bugg, et al. 1993. Drugs by design: Structure-based design, an innovative approach to developing drugs, has recently spawned many promising therapeutic agents, including several now in human trials for treating AIDS, cancer and other diseases. <i>Scientific American</i> , Dec.:92-98.
	17	Clare, et al. 1987. Three-dimensional structure of potato carboxypeptidase inhibitor in solution: A study using nuclear magnetic resonance, distance geometry, and restrained molecular dynamics. <i>Biochemistry</i> , 26:8012-8023.
	18	Crosa, et al. 1973. Molecular relationships among the <i>Salmonellae</i> . <i>J. Bacteriol.</i> , 115(1):307-315.
	19	Cwiria, et al. 1990. Peptides on phage: A vast library of peptides for identifying ligands. <i>Proc. Natl. Acad. Sci. USA</i> , 87:6378-6382.
	20	Devlin, et al. 1990. Random peptide libraries: A source of specific protein binding molecules. <i>Science</i> , 249:404-406.
	21	Edwards, B. H. 1999. <i>Salmonella</i> and <i>Shigella</i> species. <i>Clinics Lab. Med.</i> , 19(3):469-487.
	22	Erickson, J. W. 1993. Design and structure of symmetry-based inhibitors of HIV-1 protease. <i>Perspectives in Drug Discovery and Design</i> , 1:109-128.
	23	Good, et al. 1998. Antisense inhibition of gene expression in bacteria by PNA targeted to mRNA. <i>Nature Biotechnology</i> , 16:355-358

EXAMINER	DATE CONSIDERED
	1.7.03

*EXAMINER: INITIAL IF CITATION CONSIDERED. WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609. DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. ELITRA.001DV1	APPLICATION NO 09/912,020
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT		COPY OF PAPERS ORIGINALLY FILED	
(USE SEVERAL SHEETS IF NECESSARY)		APPLICANT Zyskind, et al.	MAY 15 2002
		FILING DATE July 23, 2001	GROUP 1634
		TECH CENTER 1600/2900	

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
	24 Hare, et al. 2000. Genetic footprinting in bacteria. <i>J. Bacteriol.</i> , 183(5):1694-1706.
	25 Huycke, et al. 1998. Multiple-drug resistant enterococci: The nature of the problem and an agenda for the future. <i>Emerging Infectious Diseases</i> , 4(2):239-249.
	26 Israelsen, et al. 1995. Cloning and partial characterization of regulated promoters from <i>Lactococcus lactis</i> Tn917- <i>lacZ</i> integrants with the new promoter probe vector, pAK80. <i>Applied and Environmental Microbiology</i> , 61(7):2540-2547.
	27 Kreiswirth, et al. 1983. The toxic shock syndrome exotoxin structural gene is not detectably transmitted by a prophage. <i>Nature</i> , 305:709-712.
	28 Kuroda, et al. 2001. Whole genome sequencing of methicillin-resistant <i>Staphylococcus aureus</i> . <i>The Lancet</i> , 357(9264):1225-1240.
	29 Lam, et al. 1994. Rational design of potent, bioavailable, nonpeptide cyclic ureas as HIV protease inhibitors. <i>Science</i> , 263:380-384.
	30 Leboeuf, et al. 2000. Characterization of the <i>ccpA</i> gene of <i>Enterococcus faecalis</i> : Identification of starvation-inducible proteins regulated by CcpA. <i>J. Bacteriology</i> , 182(20):5799-5806.
	31 Marrone, et al. 2000. Discovering high-affinity ligands from the computationally predicted structures and affinities of small molecules bound to a target: A virtual screening approach. <i>Perspectives in Drug Discovery and Design</i> , 20:209-230.
	32 Mestres, et al. 2000. Similarity versus docking in 3D virtual screening. <i>Perspectives in Drug Discovery and Design</i> , 20:191-207.
	33 Mojmudar, et al. 1988. Characterization of the tetracycline resistance gene of plasmid pT181 of <i>Staphylococcus aureus</i> . <i>J. Bacteriology</i> , 170(12):5522-5528.
	34 Morrissey, et al. 2000. Molecular Cloning and Analysis of a Putative Siderophore ABC Transporter from <i>Staphylococcus aureus</i> . <i>Infection and Immunity</i> , 68(11):6281-6288.
	35 Moszer, et al. 1995. <i>SubtiList</i> : A relational database for the <i>Bacillus subtilis</i> genome. <i>Microbiology</i> , 141:261-268.
	36 Moszer, I. 1998. The complete genome of <i>Bacillus subtilis</i> : From sequence annotation to data management and analysis. <i>FEBS Letters</i> , 430:28-36.
	37 MRSA genome unravelled. Abstract. 2000. <i>The Lancet</i> , 357(9264).
	38 Nallapareddy, et al. 2000. <i>Enterococcus faecalis</i> adhesin, ace, mediates attachment to extracellular matrix proteins collagen type IV and laminin as well as collagen type I. <i>Infect. Immun.</i> , 68(9):5218-5224.
	39 Neidhardt, F. C. (Ed.). 1996. <i>Escherichia coli</i> and <i>Salmonella</i> : Cellular and molecular biology, 2nd Ed., Vol. 2, pp. 2269-2271. Washington, D.C.: ASM Press.
	40 Schnappinger, et al. 1995. Extracellular expression of native human anti-lysozyme fragments in <i>Staphylococcus carnosus</i> . <i>FEMS Microbiol. Let.</i> , 129:121-127.
	41 Scott, et al. 1990. Searching for peptide ligands with an epitope library. <i>Science</i> , 249:386-390.
	42 Shuker, et al. 1996. Discovering high-affinity ligands for proteins: SAR by NMR. <i>Science</i> , 274:1531-1534.
	43 Suh, et al. 1995. Genetic and transcriptional organization of the <i>Bacillus subtilis</i> <i>spc-alpha</i> region. Database accession no. L47971 (ID: BSRPLP), XP002190118.
	44 Suh, et al. 1996. Genetic and transcriptional organization of the <i>Bacillus subtilis</i> <i>spc-alpha</i> region. <i>Gene</i> , 169:17-23.
	45 Tatusov, et al. 2000. The COG database: A tool for genome-scale analysis of protein functions and evolution. <i>Nucleic Acids Research</i> , 28(1):33-36.
	46 Van Delden, et al. 1998. Cell-to-cell signaling and <i>Pseudomonas aeruginosa</i> infections. <i>Emerging Infectious Diseases</i> , 4(4):551-560.
	47 Wagner, et al. 1987. Protein structures in solution by nuclear magnetic resonance and distance geometry: The polypeptide fold of the basic pancreatic trypsin inhibitor determined using two different algorithms, DISGEO and DISMAN. <i>J. Mol. Biol.</i> , 196:611-639.
	48 Wallis, et al. 2000. Molecular basis of <i>Salmonella</i> -induced enteritis. <i>Molec. Microb.</i> , 36(5):997-1005.
	49 Wlodawer, et al. 1993. Structure-based inhibitors of HIV-1 protease. <i>Annu. Rev. Biochem.</i> , 62:543-585.
	50 Wong, et al. 2000. Genetic footprinting with <i>mariner</i> -based transposition in <i>Pseudomonas aeruginosa</i> . <i>PNAS</i> , 97(18):10191-10196.
	51 Wüthrich, et al. 1983. Pseudo-structures for the 20 common amino acids for use in studies of protein conformations by measurements of intramolecular proton-proton distance constraints with nuclear magnetic resonance. <i>J. Mol. Biol.</i> , 169:949-961.
	52 Xia, et al. 1999. Rapid method for the identification of essential genes in <i>Staphylococcus aureus</i> . <i>Plasmid</i> , 42:144-149.

S:\D\CS\DO\H\DOH-6640.DOC:dmb - 043002

EXAMINER	DATE CONSIDERED 1.7.03
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT	

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

APPLICATION NO.
09/912,020


RECEIVED

(USE SEVERAL SHEETS IF NECESSARY)

JUL 02 2002

GROUP
1635

TECH CENTER 1600/2900

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
	1	6,228,579 B1	05/08/01	Zyskind, et al.			
	2	6,228,588 B1	05/08/01	Benton, et al.			

**COPY OF PAPERS
ORIGINALLY FILED**

[illegible][illegible]

EXAMINER

DATE CONSIDERED

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. ELITRA.001DV1	APPLICATION NO. 09/912,020
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)		APPLICANT Zyskind, et al.	RECEIVED SEP 13 2002 TECH CENTER 1600/2900
		FILING DATE July 23, 2001	GROUP 1635

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
J	1	US 2002/0058260 A1	05/16/02	Zyskind, et al.			
						COPY OF PAPERS ORIGINALLY FILED	

FOREIGN PATENT DOCUMENTS

[illegible]

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

[illegible]

S:\DOCS\DOH\DOH-7008.DOC:dmb
090602

EXAMINER	DATE CONSIDERED 1.7.03
----------	------------------------

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

